Supplementary IOL

Default banner image for Supplementary IOL
Photo of Colin Kerr

Rayner has announced that a selection of models in their Sulcoflex range of pseudophakic supplementary IOLs have received Chinese Food and Drug Administration (CFDA) approval. “After a four-year registration application – the longest in the history of Rayner – the CFDA has confirmed it’s approval of this selection of Sulcoflex IOLs. This innovation has been successfully implanted for 10 years and we are excited about launching it in a market as important as China,” said Rayner’s Commercial Director Cary Dawes. “China is Rayner’s number one distributor market in terms of size and growth, so to add the Sulcoflex platform to our offering will open up even more growth opportunities,” he said. www.rayner.com